Salvage chemotherapy after failure of targeted therapy in a child with
BRAF V600E low grade glioma
Abstract
Targeted therapies are increasingly used in the management of pediatric
low grade glioma. How-ever for patients who show resistance to these
treatments, limited options are available. We pre-sent the case of a
patient with BRAFV600 mutated low grade glioma who showed progression on
a combination of trametinib and dabrafenib. Discontinuation of treatment
was associated with a life-threatening deterioration and reintroduction
of targeted therapy had no effect. The patient eventually showed a
dramatic response to TPCV (thiguanine, procarbazine, CCNU and
vincris-tine) , which suggests a role of chemotherapy in these
situations.